Ovarian Cancer

Progress Report in Cancer Control: How Are We Doing?

Progress Report in Cancer Control: How Are We Doing?

An analysis of population data on cancer incidence, survival, and mortality revealed that early interventions and improvements to treatments contributed to a 26% decline in cancer deaths from 1991 to 2015.

Chemotherapy With Bevacizumab May Improve Some Ovarian Cancer Outcomes, Worsen Others

Chemotherapy With Bevacizumab May Improve Some Ovarian Cancer Outcomes, Worsen Others

By

First-line chemotherapy in combination with bevacizumab, compared with chemotherapy alone, may benefit patients with ovarian cancer and elevated neutrophil-to-lymphocyte ratios.

No Difference in CEA vs CA125/CEA Ratio for Identifying Ovarian Masses

No Difference in CEA vs CA125/CEA Ratio for Identifying Ovarian Masses

By

No significant difference was identified in combination CA125/CEA ratio vs CEA alone in distinguishing ovarian neoplasms from ovarian metastases.

Avastin Plus ChemoTx Approved for Advanced Ovarian Cancer After Resection

Avastin Plus ChemoTx Approved for Advanced Ovarian Cancer After Resection

By

Study patients who received Avastin plus chemotherapy followed by Avastin alone, had a greater median PFS vs patients who received chemotherapy alone (18.2 months vs 12 months; hazard ratio [HR] 0.62, 95% CI, 0.52-0.75; P<.0001).

Mirvetuximab Gets Fast Track Status for Platinum-Resistant Ovarian Cancer

Mirvetuximab Gets Fast Track Status for Platinum-Resistant Ovarian Cancer

By

Mirvetuximuab soravtansine uses a humanized FRα-binding antibody to target antibody-drug conjugates specifically to FRα-expressing cancer cells and a potent anti-tumor agent, DM4, to kill the targeted cancer cells.

Prophylactic, Extended Carboplatin Infusion Not Linked to Lower HSR in Ovarian Cancer Patients

Prophylactic, Extended Carboplatin Infusion Not Linked to Lower HSR in Ovarian Cancer Patients

By

A prophylactic, graded, extended infusion of carboplatin, compared with a shorter, standard infusion, is not associated with a reduced rate of HSRs in women with recurrent ovarian cancer.

Severe Folate Deficiency Associated With Olaparib for Relapsed Ovarian Cancer

Severe Folate Deficiency Associated With Olaparib for Relapsed Ovarian Cancer

In a case study, olaparib was found to induce folate deficiency in most patients with relapsed ovarian cancer. Researchers discuss the significance of this adverse effect and how it was managed.

Ovarian Cancer Patients May Benefit From Trabectedin With PLD

Ovarian Cancer Patients May Benefit From Trabectedin With PLD

By

For patients with platinum-sensitive recurrent ovarian cancer, trabectedin plus PLD may be beneficial.

Highly Selective, First-in-Class CDK4 Inhibitor Promising in Ovarian Cancer

Highly Selective, First-in-Class CDK4 Inhibitor Promising in Ovarian Cancer

Mice treated with 2-94 had few or no signs of lymphopenia or neutropenia, common adverse events associated with palbociclib.

Advanced Ovarian Cancer Survival Rates Longer After Primary Cytoreductive Surgery Compared With Neoadjuvant Chemotherapy

Advanced Ovarian Cancer Survival Rates Longer After Primary Cytoreductive Surgery Compared With Neoadjuvant Chemotherapy

By

Researchers found a superior survival rate in patients who received primary cytoreductive surgery as opposed to neoadjuvant chemotherapy for stage IIIC and IV high-grade serous ovarian carcinoma.

FDA Approves Multi-Cancer Treatment Drug

FDA Approves Multi-Cancer Treatment Drug

By

The FDA has approved Rubraca, a poly (ADP-ribose) polymerase inhibitor, to treat patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Pap Tests May Help Diagnose Endometrial, Ovarian Cancers

Pap Tests May Help Diagnose Endometrial, Ovarian Cancers

Genetic mutations assays using PapSEEK may facilitate the detection of certain cancers using fluids from Pap tests.

Vigil Immunotherapy and PARP 7 Treatments for Patients with Ovarian Cancer

Vigil Immunotherapy and PARP 7 Treatments for Patients with Ovarian Cancer

Vigil immunotherapy is possible for women with recurrent ovarian cancer and PARP 7 may impact ovarian cancer survival, according to two studies presented in New Orleans.

Cooling therapy for hand-foot syndrome prevention, management

Cooling therapy for hand-foot syndrome prevention, management

For patients with ovarian cancer taking pegylated liposomal doxorubicin who have hand-foot syndrome, frozen gloves and socks is a safe method of treatment.

Metformin, statins not associated with ovarian cancer

Metformin, statins not associated with ovarian cancer

The incidence of ovarian cancer was not related to metformin or statin usage among women with type 2 diabetes.

Ovarian cancer may be paternally inherited

Ovarian cancer may be paternally inherited

By

The disease allele may be passed from affected grandmother to granddaughter through the father's inherited genes.

Ovarian cancer risk reduced with oral contraceptives

Ovarian cancer risk reduced with oral contraceptives

By

The use of oral contraceptives did not reduce the risks of breast cancer or colorectal cancer.

Assessing the impact of antidepressants on ovarian cancer risk

Assessing the impact of antidepressants on ovarian cancer risk

By

Past epidemiological investigations resulted in inconsistent reports on the affiliation between antidepressants and the risk of ovarian cancer.

Ovarian cancer screening: updated recommendations from the USPSTF

Ovarian cancer screening: updated recommendations from the USPSTF

By

The USPSTF has issued an updated recommendation statement on ovarian cancer screening.

Ovarian cancer patients may benefit from added hyperthermic intraperitoneal chemotherapy

Ovarian cancer patients may benefit from added hyperthermic intraperitoneal chemotherapy

The addition of HIPEC resulted in longer recurrence-free and overall survival among patients with ovarian cancer.

Multi-analyte blood test detects 8 common cancers

Multi-analyte blood test detects 8 common cancers

A multi-analyte blood test, CancerSEEK, can detect 8 common cancer types, with high sensitivity and specificity.

Ovarian cancer screening: a USPSTF recommendation statement

Ovarian cancer screening: a USPSTF recommendation statement

By

The USPSTF states that the harms of screening for ovarian cancer in asymptomatic women outweigh the benefits.

Is our makeup secretly hurting us?

Is our makeup secretly hurting us?

By

Using powder makeup containing talc may increase the risk of ovarian cancer.

Multigene tests can change breast, ovarian cancer management

Multigene tests can change breast, ovarian cancer management

For hereditary breast, ovarian cancer, multigene testing can influence clinical treatment options.

Reducing chemo dose raises mortality in ovarian cancer

Reducing chemo dose raises mortality in ovarian cancer

For women with ovarian cancer, reducing chemotherapy dose was linked to worse survival regardless of BMI.

Daily aspirin may protect against ovarian cancer

Daily aspirin may protect against ovarian cancer

Regular low-dose aspirin use lowered ovarian cancer risk by 20% in 12 studies involving nearly 20,000 women.

Sign Up for Free e-newsletters